Selected research
Industry Research
Peptide Antibiotics Industry Research Report 2026
Market perspective
The global Peptide Antibiotics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Peptide Antibiotics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Peptide Antibiotics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Peptide Antibiotics include AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Pacgen Life Science Corporation, Phosphagenics, Savara Pharmaceuticals, Theravance and Vicuron Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Peptide Antibiotics market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide Antibiotics Market by Company
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Pacgen Life Science Corporation
Phosphagenics
Savara Pharmaceuticals
Theravance
Vicuron Pharmaceuticals
GlaxoSmithKline
Pfizer
Eli Lilly
Novartis
Peptide Antibiotics Segment by Type
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics
Peptide Antibiotics Segment by Application
Pharma & Healthcare
Food Industry
Commodities
Other
Peptide Antibiotics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Peptide Antibiotics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Peptide Antibiotics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ribosomal Synthesized Peptide Antibiotics
- Non-Ribosomally Synthesized Peptide Antibiotics
Applications
- Pharma & Healthcare
- Food Industry
- Commodities
- Other
Companies covered
- AMP Therapeutics
- Hospira
- Kasten
- Madam Therapeutics
- Pacgen Life Science Corporation
- Phosphagenics
- Savara Pharmaceuticals
- Theravance
- Vicuron Pharmaceuticals
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Peptide Antibiotics Market Size (2021-2032)
- 2.2.2 Global Peptide Antibiotics Sales (2021-2032)
- 2.2.3 Global Peptide Antibiotics Market Average Price (2021-2032)
- 2.3 Peptide Antibiotics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ribosomal Synthesized Peptide Antibiotics
- 2.3.3 Non-Ribosomally Synthesized Peptide Antibiotics
- 2.4 Peptide Antibiotics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharma & Healthcare
- 2.4.3 Food Industry
- 2.4.4 Commodities
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Peptide Antibiotics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Peptide Antibiotics Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Peptide Antibiotics Revenue of Manufacturers (2021-2026)
- 3.4 Global Peptide Antibiotics Average Price by Manufacturers (2021-2026)
- 3.5 Global Peptide Antibiotics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Peptide Antibiotics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide Antibiotics, Product Type & Application
- 3.8 Global Manufacturers of Peptide Antibiotics, Established Date
- 3.9 Global Peptide Antibiotics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AMP Therapeutics
- 4.1.1 AMP Therapeutics Company Information
- 4.1.2 AMP Therapeutics Business Overview
- 4.1.3 AMP Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AMP Therapeutics Peptide Antibiotics Product Portfolio
- 4.1.5 AMP Therapeutics Recent Developments
- 4.2 Hospira
- 4.2.1 Hospira Company Information
- 4.2.2 Hospira Business Overview
- 4.2.3 Hospira Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hospira Peptide Antibiotics Product Portfolio
- 4.2.5 Hospira Recent Developments
- 4.3 Kasten
- 4.3.1 Kasten Company Information
- 4.3.2 Kasten Business Overview
- 4.3.3 Kasten Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Kasten Peptide Antibiotics Product Portfolio
- 4.3.5 Kasten Recent Developments
- 4.4 Madam Therapeutics
- 4.4.1 Madam Therapeutics Company Information
- 4.4.2 Madam Therapeutics Business Overview
- 4.4.3 Madam Therapeutics Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Madam Therapeutics Peptide Antibiotics Product Portfolio
- 4.4.5 Madam Therapeutics Recent Developments
- 4.5 Pacgen Life Science Corporation
- 4.5.1 Pacgen Life Science Corporation Company Information
- 4.5.2 Pacgen Life Science Corporation Business Overview
- 4.5.3 Pacgen Life Science Corporation Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio
- 4.5.5 Pacgen Life Science Corporation Recent Developments
- 4.6 Phosphagenics
- 4.6.1 Phosphagenics Company Information
- 4.6.2 Phosphagenics Business Overview
- 4.6.3 Phosphagenics Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Phosphagenics Peptide Antibiotics Product Portfolio
- 4.6.5 Phosphagenics Recent Developments
- 4.7 Savara Pharmaceuticals
- 4.7.1 Savara Pharmaceuticals Company Information
- 4.7.2 Savara Pharmaceuticals Business Overview
- 4.7.3 Savara Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Savara Pharmaceuticals Peptide Antibiotics Product Portfolio
- 4.7.5 Savara Pharmaceuticals Recent Developments
- 4.8 Theravance
- 4.8.1 Theravance Company Information
- 4.8.2 Theravance Business Overview
- 4.8.3 Theravance Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Theravance Peptide Antibiotics Product Portfolio
- 4.8.5 Theravance Recent Developments
- 4.9 Vicuron Pharmaceuticals
- 4.9.1 Vicuron Pharmaceuticals Company Information
- 4.9.2 Vicuron Pharmaceuticals Business Overview
- 4.9.3 Vicuron Pharmaceuticals Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio
- 4.9.5 Vicuron Pharmaceuticals Recent Developments
- 4.10 GlaxoSmithKline
- 4.10.1 GlaxoSmithKline Company Information
- 4.10.2 GlaxoSmithKline Business Overview
- 4.10.3 GlaxoSmithKline Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 GlaxoSmithKline Peptide Antibiotics Product Portfolio
- 4.10.5 GlaxoSmithKline Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Peptide Antibiotics Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 Eli Lilly
- 4.12.1 Eli Lilly Company Information
- 4.12.2 Eli Lilly Business Overview
- 4.12.3 Eli Lilly Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Eli Lilly Peptide Antibiotics Product Portfolio
- 4.12.5 Eli Lilly Recent Developments
- 4.13 Novartis
- 4.13.1 Novartis Company Information
- 4.13.2 Novartis Business Overview
- 4.13.3 Novartis Peptide Antibiotics Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Novartis Peptide Antibiotics Product Portfolio
- 4.13.5 Novartis Recent Developments
5 Global Peptide Antibiotics Market Scenario by Region
- 5.1 Global Peptide Antibiotics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Peptide Antibiotics Sales by Region: 2021-2032
- 5.2.1 Global Peptide Antibiotics Sales by Region: 2021-2026
- 5.2.2 Global Peptide Antibiotics Sales by Region: 2027-2032
- 5.3 Global Peptide Antibiotics Revenue by Region: 2021-2032
- 5.3.1 Global Peptide Antibiotics Revenue by Region: 2021-2026
- 5.3.2 Global Peptide Antibiotics Revenue by Region: 2027-2032
- 5.4 North America Peptide Antibiotics Market Facts & Figures by Country
- 5.4.1 North America Peptide Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Peptide Antibiotics Sales by Country (2021-2032)
- 5.4.3 North America Peptide Antibiotics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Peptide Antibiotics Market Facts & Figures by Country
- 5.5.1 Europe Peptide Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Peptide Antibiotics Sales by Country (2021-2032)
- 5.5.3 Europe Peptide Antibiotics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Peptide Antibiotics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Peptide Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Peptide Antibiotics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Peptide Antibiotics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Peptide Antibiotics Market Facts & Figures by Country
- 5.7.1 South America Peptide Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Peptide Antibiotics Sales by Country (2021-2032)
- 5.7.3 South America Peptide Antibiotics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Peptide Antibiotics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Peptide Antibiotics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Peptide Antibiotics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Peptide Antibiotics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Peptide Antibiotics Sales by Type (2021-2032)
- 6.1.1 Global Peptide Antibiotics Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Peptide Antibiotics Sales Market Share by Type (2021-2032)
- 6.2 Global Peptide Antibiotics Revenue by Type (2021-2032)
- 6.2.1 Global Peptide Antibiotics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Peptide Antibiotics Revenue Market Share by Type (2021-2032)
- 6.3 Global Peptide Antibiotics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Peptide Antibiotics Sales by Application (2021-2032)
- 7.1.1 Global Peptide Antibiotics Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Peptide Antibiotics Sales Market Share by Application (2021-2032)
- 7.2 Global Peptide Antibiotics Revenue by Application (2021-2032)
- 7.2.1 Global Peptide Antibiotics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Peptide Antibiotics Revenue Market Share by Application (2021-2032)
- 7.3 Global Peptide Antibiotics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Peptide Antibiotics Value Chain Analysis
- 8.1.1 Peptide Antibiotics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Peptide Antibiotics Production Mode & Process
- 8.2 Peptide Antibiotics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Peptide Antibiotics Distributors
- 8.2.3 Peptide Antibiotics Customers
9 Global Peptide Antibiotics Analyzing Market Dynamics
- 9.1 Peptide Antibiotics Industry Trends
- 9.2 Peptide Antibiotics Industry Drivers
- 9.3 Peptide Antibiotics Industry Opportunities and Challenges
- 9.4 Peptide Antibiotics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst